Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: July 2008
-
C5 (UK) will be holding its Biotech Patenting conference on September 23-24, 2008 in London, England. The conference will allow attendees to: • Analyze the practical impact of recent changes at the UK-IPO, EPO, and USPTO;• Increase knowledge of developments in follow-on biologics and antibody technologies in the patent area;• Manage the challenges posed by…
-
By Kevin E. Noonan — One of the promises of the genomics revolution of the late 20th Century is the advent of personalized medicine. The belief was (and is) that the unfolding understanding of genetic variation stemming from sequence analysis of genes known or discovered to be involved in an individual’s response to…
-
By Donald Zuhn — The Intellectual Property Owners Association (IPO) reported today on data compiled by Esther Kepplinger, the Director of Patent Operations for Wilson Sonsini Goodrich & Rosati, which the IPO believes "has received little attention and has contributed to misunderstanding of patenting trends." In particular, Ms. Kepplinger’s analysis shows that Requests…
-
By Christopher P. Singer — In a July 16, 2008 press release, the U.S. Patent and Trademark Office announced it will extend the duration, increase the maximum number of applications, and expand the scope of applications eligible to participate in its Peer Review Pilot program. The extension and expansion became effective on July…
-
By Christopher P. Singer — In a Notice published in the Federal Register (73 Fed. Reg. 42781) on Wednesday, July 23, 2008, the U.S. Patent and Trademark Office discussed the general scope of the foreign filing licenses that it issues. While the Notice states that it serves to clarify the existing law and…
-
By Donald Zuhn and Benjamin Huber — Last Friday, the U.S. Patent and Trademark Office and USPTO Director Jon Dudas filed their opening brief in the Tafas v. Dudas appeal. As we previously reported, the Patent Office and Director Dudas had until July 18th (i.e., sixty days from the May 19th docketing date)…
-
By Kevin E. Noonan — Sanity may be returning to the Federal Circuit’s treatment of two issues, obviousness and inequitable conduct. In Eisai Co. v. Dr. Reddy’s Laboratories, Inc., the Court (in an opinion by Judge Rader joined by Judges Linn and Prost) affirmed the District Court’s determination that the patent-in-suit, U.S. Patent…
-
By Donald Zuhn — Yesterday, we reported on the Patent Office’s publication of a Notice in the Federal (73 Fed. Reg. 32559) requesting that interested members of the public comment on the Office’s estimates for any additional burdens imposed on applicants by the new appeals rules. In a departure from recent Patent Office…
-
By Sherri Oslick — In a transaction merging two major players in the generic pharmaceutical arena, Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced late last week that they have entered into an agreement by which Teva will acquire Barr for $7.46 billion plus the assumption of $1.5 billion in debt. The…
-
By Kevin E. Noonan and Donald Zuhn — The U.S. Patent and Trademark Office has attempted (with varying levels of success) to implement a number of new rules packages in the past two years, including new continuation and claims rules, alternative claiming rules, and IDS rules, but none of these rules packages has…
Patent Docs 